CD4 and graft versus host disease: Despite this lower dose, B6.lpr DN T cells significantly enhanced GVHD survival compared with B6.gld DN T cells (Fig. 7C; log rank test p = 0.0006), whereas B6.gld DN T cell-treated mice had a rate of survival comparable to mice treated with BM+CD4+ (Fig. 7C).